Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3903 ARTÍCULOS , VIENDO DEL 526 AL 540

Aldehyde dehydrogenase inhibition generates a reactive dopamine metabolite autotoxic to dopamine neurons

Doorn JA, Florang VR, Schamp JH, Vanle BC.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1(0 1):S73-5. doi: 10.1016/S1353-8020(13)70019-1.

Quantification of α-synuclein in cerebrospinal fluid: how ideal is this biomarker for Parkinson's disease?

Mollenhauer B.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S76-9. doi: 10.1016/S1353-8020(13)70020-8.

Modeling Lewy pathology propagation in Parkinson's disease

Luk KC, Lee VM.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1(0 1):S85-7. doi: 10.1016/S1353-8020(13)70022-1.

Autonomic disorders predicting Parkinson's disease

Palma JA, Kaufmann H.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1(0 1):S94-8. doi: 10.1016/S1353-8020(13)70024-5.

Blood-based biomarkers for Parkinson's disease

Chahine LM, Stern MB, Chen-Plotkin A.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1(0 1):S99-103. doi: 10.1016/S1353-8020(13)70025-7.

Treatment of the sleep disorders associated with Parkinson's disease

Trotti LM, Bliwise DL.

Neurotherapeutics. 2014 Jan;11(1):68-77. doi: 10.1007/s13311-013-0236-z.

Neuropsychological outcomes after psychosocial intervention for depression in Parkinson's disease

Dobkin RD, Tröster AI, Rubino JT, Allen LA, Gara MA, Mark MH, Menza M.

J Neuropsychiatry Clin Neurosci. 2014 Winter;26(1):57-63. doi: 10.1176/appi.neuropsych.12120381.

Progressive parkinsonism, balance difficulties, and supranuclear gaze palsy

Erro R, Lees AJ, Moccia M, Picillo M, Penco S, Mosca L, Vitale C, Barone P.

JAMA Neurol. 2014 Jan;71(1):104-7. doi: 10.1001/jamaneurol.2013.5149.

Use of hyposmia and other non-motor symptoms to distinguish between drug-induced parkinsonism and Parkinson's disease

Morley JF, Duda JE.

J Parkinsons Dis. 2014;4(2):169-73. doi: 10.3233/JPD-130299.

Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease

Connolly B, Fox SH.

Neurotherapeutics. 2014 Jan;11(1):78-91. doi: 10.1007/s13311-013-0238-x.

Parkinson's disease mild cognitive impairment: application and validation of the criteria

Geurtsen GJ, Hoogland J, Goldman JG, Schmand BA, Tröster AI, Burn DJ, Litvan I; MDS Study Group on the Validation of PD-MCI Criteria.

J Parkinsons Dis. 2014;4(2):131-7. doi: 10.3233/JPD-130304.

Complete and readily reversible blocking of striatal DaTscan binding by methylphenidate

Cheng G, Morley JF.

Clin Nucl Med. 2014 Feb;39(2):211-3. doi: 10.1097/RLU.0000000000000307.

Using mass spectrometry-based peptidomics to understand the brain and disorders such as Parkinson's disease and schizophrenia

Cafe-Mendes CC, Ferro ES, Britto LR, Martins-de-Souza D.

Curr Top Med Chem. 2014;14(3):369-81. doi: 10.2174/1568026613666131204120747.

Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?

Hung AY, Schwarzschild MA.

Neurotherapeutics. 2014 Jan;11(1):34-46. doi: 10.1007/s13311-013-0239-9.

Brain 18F-FDG PET imaging in the differential diagnosis of parkinsonism

Akdemir ÜÖ, Tokçaer AB, Karakuş A, Kapucu LÖ.

Clin Nucl Med. 2014 Mar;39(3):e220-6. doi: 10.1097/RLU.0000000000000315.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias